Flexion's FX005 meets OA of the knee endpoint

Flexion Therapeutics Inc. (Woburn, Mass.) said single intra-articular injections FX005 met the primary endpoint of improving WOMAC pain subscale scores from baseline to week four vs. placebo in a Phase II trial to treat pain in patients with osteoarthritis (OA) of knee. The double-blind, international trial enrolled 104 patients. Flexion plans to start a dose-ranging Phase IIb trial of FX005 in 1H13. FX005 is an inhibitor of p38 mitogen-activated protein kinase ( p38 MAPK; MAPK14). ...